Division of Adult Psychiatry, Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
Division of Psychiatric Specialties, Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.
Transl Psychiatry. 2021 Jan 14;11(1):51. doi: 10.1038/s41398-020-01179-5.
Several studies suggested that 5-HT receptor (5-HTR) blockade may provide a more favorable efficacy and side-effect profile to antipsychotic treatment. We hypothesized that a combined haloperidol (a D receptor (DR) antagonist) and MDL-100,907 (a 5-HTR antagonist) treatment would reverse the side effects and the neurochemical alterations induced by haloperidol alone and would potentialize its efficacy. We thus chronically treated male Mdr1a knock-out rats with several doses of haloperidol alone or in combination with a saturating dose of a MDL-100,907. Receptor occupancy at clinically relevant levels was validated with a dual-radiotracer in-vivo SPECT imaging of DR and 5-HTR occupancy. Experimental tests of efficacy (dizocilpine-disrupted prepulse inhibition (PPI) of the startle reflex) and side effects (catalepsy, vacuous chewing movements) were performed. Finally, a second dual-radiotracer in-vivo SPECT scan assessed the neurochemical changes induced by the chronic treatments. Chronic haloperidol failed to reverse PPI disruption induced by dizocilpine, whilst administration of MDL-100,907 along with haloperidol was associated with a reversal of the effect of dizocilpine. Haloperidol at 0.5 mg/kg/day and at 1 mg/kg/day induced catalepsy that was significantly alleviated (by ~50%) by co-treatment with MDL-100,907 but only at 0.5 mg/kg/day dose of haloperidol. Chronic haloperidol treatment, event at doses as low as 0.1 mg/kg/day induced a significant upregulation of the DR in the striatum (by over 40% in the nucleus accumbens and over 20% in the caudate-putamen nuclei), that was not reversed by MDL-100,907. Finally, an upregulation of 5-HTR after chronic haloperidol treatment at a moderate dose only (0.25 mg/kg/day) was demonstrated in frontal cortical regions and the ventral tegmental area. Overall, a partial contribution of a 5-HTR antagonism to the efficacy and side-effect profile of antipsychotic agents is suggested.
几项研究表明,5-羟色胺受体(5-HTR)阻断可能为抗精神病治疗提供更有利的疗效和副作用特征。我们假设,联合使用氟哌啶醇(D 受体(DR)拮抗剂)和 MDL-100,907(5-HTR 拮抗剂)治疗将逆转氟哌啶醇单独引起的副作用和神经化学改变,并增强其疗效。因此,我们用几种剂量的氟哌啶醇单独或与饱和剂量的 MDL-100,907 对雄性 Mdr1a 敲除大鼠进行慢性治疗。用 DR 和 5-HTR 占有率的双重放射性示踪剂体内 SPECT 成像来验证临床相关水平的受体占有率。进行了疗效实验测试(惊恐反射的双脉冲抑制(PPI)被地西泮破坏)和副作用(僵住,空咀嚼运动)。最后,进行了第二次双重放射性示踪剂体内 SPECT 扫描,以评估慢性治疗引起的神经化学变化。慢性氟哌啶醇未能逆转地西泮引起的 PPI 破坏,而 MDL-100,907 与氟哌啶醇一起给药与地西泮的作用逆转有关。氟哌啶醇 0.5mg/kg/天和 1mg/kg/天诱导僵住,而与 MDL-100,907 共同治疗可显著缓解(约 50%),但仅在氟哌啶醇 0.5mg/kg/天剂量时。慢性氟哌啶醇治疗,即使剂量低至 0.1mg/kg/天,也会导致纹状体中 DR 的显著上调(在伏隔核中上调超过 40%,在尾壳核中上调超过 20%),而 MDL-100,907 则不会逆转这种上调。最后,仅在中等剂量(0.25mg/kg/天)的慢性氟哌啶醇治疗后,在额叶皮质区域和腹侧被盖区显示出 5-HTR 的上调。总体而言,提示 5-HTR 拮抗剂对抗精神病药物的疗效和副作用特征有一定的贡献。